Alex Delaney-Gesing

Edward Holland, MD, discusses Aurion Biotech's investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.

Edward Manche, MD, discusses results from his presentation regarding outcomes of corneal crosslinking keratoconus in a pediatric population.

Heru Inc., announced Thursday that it has partnered with Vision Source on the commercial availability launch of re:Vive, a wearable diagnostics and visual field application.

Ed Hu, MD, PhD, shares highlights from his paper analyzing three years' worth of his own postop data on comparative lens rotations in toric IOL platforms.

Mitch Shultz, MD, speaks on the capabilities of a cloud-based database system to look at energy-fluid metrics, provide surgeons with the capacity to refine procedures and give patients better outcomes.

Elizabeth Yeu, MD, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of TP03 for the treatment of patients diagnosed with Demodex blepharitis.

Colman R. Kraff, MD, shares highlights of a study evaluating the safety and efficacy of the use of the iDesign 2.0 Refractive Studio for the treatment of patients with hyperopia and myopia.

Chuck Hess shares an update on Bausch + Lomb's latest developments in surgical technology, as well as how the company has adapted its operations during the pandemic.

Jag Dosanjh, senior vice president of U.S. Eye Care, Allergan, an AbbVie company, offers a preview of the company's latest innovations, developments, and what attendees can look forward to at ASCRS 2021.

Alkeus Pharmaceuticals, Inc, announced Thursday that the FDA has granted Breakthrough Therapy Designation (BTS) for ALK-001 (C20-D3-vitamin A) for the treatment of Stargardt disease.

The company, formerly called BELKIN Laser, announced Thursday that it will begin operating under the new name BELKIN Vision.

ASCRS has issued a statement calling on Aetna to drop a new prior authorization policy it implemented last week that delays cataract surgeries.

Uday Devgan, MD, FACS, of Devgan Eye Surgery in Los Angeles and Beverly Hills, CA, answers a few key questions his patients have asked when considering cataract surgery.

Santen Inc. announced Thursday that the U.S. FDA has approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops to treat vernal keratoconjunctivitis (VKC).

If approved, PDS ranibizumab would become the first and only eye implant with continuous drug delivery offering people with wet AMD.

In recognition of Cataract Awareness Month.

Oyster Point Pharma announced today the enrollment of the first participant in its OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray to treat stage 1 neurotrophic keratopathy (NK).

In recognition of Cataract Awareness Month.

In recognition of Cataract Awareness Month, Fasika Woreta, MD, MPH, discusses IOL options for cataract patients.

Clearside Biomedical, Inc. reported today positive safety results from Cohort 1 of its ongoing OASIS phase1/2a clinical trial of CLS-AX for the treatment of wet AMD.

Thomas Brunner, president & CEO, Glaucoma Research Foundation, San Francisco, CA, shares his thoughts on how living through a pandemic has influenced and altered his perspective on life — both personally and professionally — for the better.

EyeGate Pharmaceuticals, Inc.'s lead product candidate is designed to treat dry eye disease-induced ocular surface inflammation.

Mark Packer, MD, offers personal insight in honor of Cataract Awareness Month.

More Americans have used and continue to use teleheath for mental health care. according to a recent online poll by the American Psychiatric Association.

Oluwatosin U. Smith, MD, Glaucoma Associates of Texas, offers an update on optimization and surgical modifications of newer glaucoma surgeries in preop and postop settings.

Ophthalmologists and industry KOLs share what lingers on their minds at the end of the day.

The U.S. Patent and Trademark Office issued today two patents to Ocuphire Pharma covering the late-stage product candidate Nyxol (phentolamine mesylate).